Exscientia plc (NASDAQ:EXAI - Get Free Report) shares were up 4.5% during trading on Wednesday . The company traded as high as $5.13 and last traded at $5.13. Approximately 183,458 shares traded hands during trading, a decline of 71% from the average daily volume of 639,510 shares. The stock had previously closed at $4.91.
Analyst Upgrades and Downgrades
A number of research analysts have commented on EXAI shares. Barclays restated an "equal weight" rating and set a $5.00 price target on shares of Exscientia in a research note on Tuesday, August 13th. TD Cowen restated a "hold" rating on shares of Exscientia in a research note on Friday, August 9th.
Get Our Latest Stock Report on EXAI
Exscientia Stock Up 1.0 %
The business's 50 day moving average price is $5.32 and its 200-day moving average price is $5.34. The company has a debt-to-equity ratio of 0.06, a current ratio of 5.93 and a quick ratio of 5.93. The company has a market cap of $599.60 million, a P/E ratio of -3.84 and a beta of 0.85.
Exscientia (NASDAQ:EXAI - Get Free Report) last posted its earnings results on Thursday, August 15th. The company reported ($0.36) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.31) by ($0.05). The firm had revenue of $5.60 million during the quarter. Exscientia had a negative net margin of 620.99% and a negative return on equity of 37.56%. On average, analysts anticipate that Exscientia plc will post -1.25 earnings per share for the current fiscal year.
Institutional Trading of Exscientia
Hedge funds and other institutional investors have recently modified their holdings of the stock. GAMMA Investing LLC grew its holdings in Exscientia by 112.1% during the 1st quarter. GAMMA Investing LLC now owns 4,356 shares of the company's stock worth $25,000 after acquiring an additional 2,302 shares during the period. China Universal Asset Management Co. Ltd. boosted its position in shares of Exscientia by 76.8% during the first quarter. China Universal Asset Management Co. Ltd. now owns 9,274 shares of the company's stock worth $53,000 after purchasing an additional 4,029 shares in the last quarter. Vanguard Personalized Indexing Management LLC bought a new position in shares of Exscientia during the second quarter worth $54,000. Walled Lake Planning & Wealth Management LLC bought a new position in shares of Exscientia during the fourth quarter worth $64,000. Finally, Federated Hermes Inc. bought a new position in shares of Exscientia during the second quarter worth $115,000. Institutional investors and hedge funds own 41.58% of the company's stock.
About Exscientia
(
Get Free Report)
Exscientia plc, an artificial intelligence (AI) driven Pharma-tech company, engages in design and develop differentiated medicines for diseases with high unmet patient needs. The company's lead product candidate GTAEXS617, a CDK7 inhibitor, which is currently in a Phase 1/2 trial to manage the potential toxicities associated with CDK7 as well as optimizing pharmacokinetics for maximizing on-target efficacy.
Read More
Before you consider Exscientia, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Exscientia wasn't on the list.
While Exscientia currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
